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A B S T R A C T
Purpose
Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men
with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited
number of patients.We investigate the impact of site ofmetastases onOS of a substantial sample of
men with mCRPC who received docetaxel chemotherapy in nine phase III trials.
Patients and Methods
Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were
combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN
(with no visceral metastases), any lung metastases (but no liver), and any liver metastases.
Results
Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%)
and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months).
Althoughmenwith lungmetastases had better median OS (19.4months) comparedwithmenwith liver
metastases, they had signiﬁcantly worse median survival duration than men with nonvisceral bone
metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled
hazard ratios for death in men with lung metastases compared with men with bone with or without LN
metastases and in men with any liver metastases compared with men with lung metastases were 1.14
(95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P , .0001), respectively.
Conclusion
Speciﬁc sites of metastases in men with mCRPC are associated with differential OS, with suc-
cessive increased lethality for lung and liver metastases compared with bone and nonvisceral
involvement. These data may help in treatment decisions, the design of future clinical trials, and
understanding the variation in biology of different sites of metastases in men with mCRPC.
J Clin Oncol 34:1652-1659. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Several studies have identiﬁed the presence of
visceral disease as an important adverse prog-
nostic factor of overall survival (OS) in men with
metastatic castration-resistant prostate cancer
(mCRPC).1-9 More recent analyses have dem-
onstrated that the presence of liver metastases
seems to be an important adverse predictor of OS
in men with mCRPC.4-9 However, because liver
and lung metastases have traditionally been
relatively rare events in patients with mCRPC,
these observations are based on analyses of rel-
atively small numbers of patients with visceral
metastases; thus, estimated hazard ratios (HRs)
may be unstable. Amore accurate characterization of
the impact of site of metastases on OS has the
potential to inﬂuence therapeutic approaches, trial
stratiﬁcation, and patient counseling.
Therefore, a meta-analysis of phase III trials
of men with mCRPC was undertaken, with the
expectation that such an approach would lead
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to a greater precision in detecting the impact of the site of
metastases on OS. We hypothesized that patients with lung
metastases would have a shorter median OS time than patients
with bone metastases and that patients with liver metastases
would, in turn, have a shorter median OS time than patients
with mCRPC and lung metastases (with or without bone
involvement). Because docetaxel was used as a standard of care
in the majority of trials available for analysis and because in
clinical practice chemotherapy was used preferentially in oth-
erwise ﬁt patients with visceral metastases, we elected to include
only trials that included docetaxel.
PATIENTS AND METHODS
Trial Inclusion Criteria
We performed a systematic search of published literature from
January 2004 to July 2015 and identiﬁed candidate studies using
PubMed and ClinicalTrials.gov that included all phase III trials of
docetaxel versus docetaxel plus an experimental agent that were
reported between 1999 and 2015.10-19 To be included in this meta-
analysis, a trial had to satisfy the following inclusion criteria: there was
institutional review board approval; the study was a phase III trial in
which men had received docetaxel (in studies with a non–docetaxel-
containing arm [SWOG 9916 and TAX 327] men not receiving docetaxel
were excluded from the analysis); patients had chemotherapy-naı¨ve
mCRPC; OS was the primary end point; and all patients provided written
informed consent.
Data
We requested the following individual patient data from each
identiﬁed trial: date of random assignment, date of last observation or
follow-up, date of death, OS status at the date of last observation, cause
of death, treatment assignment, date of birth (or age in years), date of
initial diagnosis, date of metastatic diagnosis, hemoglobin, prostate-
speciﬁc antigen (PSA), performance status, alkaline phosphatase,
creatinine, testosterone, Gleason score, prior radiation therapy, prior
hormone therapy, hormonal therapy agents, luteinizing hormone–
releasing hormone agonists, site of metastases at baseline, and strat-
iﬁcation factors. Site(s) of metastases at baseline was obtained from the
case report forms; imaging was not centrally reviewed. In all trials,
patients underwent staging with standard imaging tests (eg, bone scan,
computed tomography scans), as indicated by the individual trial’s
eligibility and baseline test requirements.9-18 Data were submitted to
the ﬁrst author at the Department of Biostatistics and Bioinformatics at
Duke University, and the analysis was approved by the Duke Insti-
tutional Review Board.
Classification of Site of Metastases
Patients were classiﬁed according to the site of their metastatic
disease in one of the following two mutually exclusive groups: non-
visceral and visceral disease (Table 1). Visceral disease was broadly
deﬁned as soft tissue metastases other than lymph node (LN) meta-
stases and included metastatic disease to lung, liver, adrenal glands,
brain, and other sites (unspeciﬁed). Visceral disease patients were, in
turn, placed in one of the following three categories: any patient with
liver metastases was categorized as having liver metastases even if they
had other metastatic sites; patients with lung metastases were denoted
as having lung metastases, unless they also had liver metastases; and all
other patients with visceral disease were categorized as having non-
hepatic, nonpulmonary visceral metastases (such as adrenal, kidney,
and others). In the nonvisceral disease group, patients were classiﬁed as
either having LN-only disease or bone metastases with or without
nodal involvement.
Statistical Analysis
The primary end point was OS, deﬁned as the interval between date of
random assignment and date of death from any cause. The primary goals of
this analysis were to estimate the pooled HR and to test the following two
hypotheses: that patients with lungmetastases would have a shortermedianOS
time than patients with bonemetastasis, and that patients with liver metastases
would, in turn, have a shortermedian OS time than patients withmCRPC and
lung metastases (with or without bone involvement). In addition, secondary
analysis was performed to estimate theOS distribution by the site ofmetastases
categorized as LN only, bone with or without LN involvement, and visceral
disease. Furthermore, analyses were performed to estimate the pooled HR for
death in patients with LN-onlymetastases versus patients with bonemetastases
with or without nodal involvement and in patients with liver metastases versus
those with bone disease.
The statistical analysis followed the standard meta-analytic
procedure using a two-stage approach.20,21 In the ﬁrst stage, each
clinical trial was analyzed separately to obtain trial-speciﬁc estimates
of the previously mentioned HRs. The trial-speciﬁc estimates were
then combined in a weighted form to obtain an overall estimate of the
HRs and their estimated variances.21 It is noted that Whitehead and
Whitehead required that the effect size be normally distributed,
which is not the case for the log HR estimators.20 However, estimators
of the coefﬁcients in the Cox regression model, which are the log-
arithms of the HR estimators, have asymptotic normal distributions.
Therefore, we derived our results in two steps. We ﬁrst computed
weighted average coefﬁcients, 95% CIs, and the Q and I2 statistics for
the coefﬁcients. Next, we took the exponential of the coefﬁcients and
were able to compute the 95% CIs. We used the variance formula for
the log-normal distribution to compute the variance of the summary
HRs.
We used the Q and I2 statistics to test for between-study hetero-
geneity. The Q statistic was used to test for the homogeneity of the HRs
across the nine studies, whereas the I2 statistic described the proportion of
Table 1. Classiﬁcation of Site of Metastases by Mutually Exclusive Categories
Site of Metastases Presence of LN Metastases Presence of Bone Metastases Presence of Visceral Metastases Category
LN only Yes No No LN
Bone only No Yes No Bone
Bone with LN involvement Yes Yes No Bone
Lung No/Yes No Yes Lung
Lung No/Yes Yes Yes Lung
Liver No/Yes No Yes Liver
Liver with any visceral disease No/Yes No Yes Liver
Liver No/Yes Yes Yes Liver
Liver with any visceral disease No/Yes Yes Yes Liver
Abbreviation: LN, lymph node.
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the total variation in the study estimates that was a result of heterogeneity.
In the event that the Q (and I2) statistic was signiﬁcant (ie, P , .05), the
random effect approach became the primary analysis.
An intent-to-treat analysis was applied within each clinical trial,
with the analysis population based on all randomly assigned patients.
In addition, the proportional hazards model was used within
each trial to estimate the HR adjusting for the following baseline
prognostic variables that were common in the nine trials: age, per-
formance status, and PSA. Furthermore, the Kaplan-Meier product-
limit approach was used to estimate the OS distribution by the
metastatic site.
Because we were testing two hypotheses, the Bonferroni correction
was used to adjust for the type I error rate. P , .025 was considered
statistically signiﬁcant, and all P values were based on two-sided tests. We
summarized the results by means of forest plots, and individual and pooled
HR estimates were presented with 95% CIs.
RESULTS
Trials Identified
Figure 1 presents the PRISMA diagram of how the trials were
identiﬁed and screened. Ten trials met the inclusion criteria. These
were SWOG 9916,10 TAX 327,11 Androgen-Independent Prostate
Cancer Study of Calcitriol Enhancing Taxotere (ASCENT),12
Cancer and Leukemia Group B (CALGB) 90401,13 Endothelin A
Use (ENTHUSE) 33,14 SWOG 0421,15 VENICE,16 READY,17
MAINSAIL,18 and SYNERGY.19 Of these 10 trials, nine sponsors
were willing to share the data; the tenth sponsor became ﬁnancially
insolvent and was unable to provide the trial data.12
Table 2 lists the trials that were included in this meta-analysis.
A total of 8,820 men with mCRPC who were treated with docetaxel
or a docetaxel-containing regimen were enrolled from October
1999 to November 2012. Themedian age was 68 years, the majority
of men were white, and 94% of them had a performance status
of 0 or 1 (Table 2). The median hemoglobin, PSA, and alkaline
phosphatase levels were 12.9 g/dL, 97 ng/mL, and 138 U/L,
respectively. The median follow-up time among surviving
patients was 21.8 months (range, 0 to 91.2 months), with a
total of 5,470 deaths.
Distribution of Metastatic Site
Most patients were in the bone metastases group (n = 6,356;
72.8%); 42.9% of the entire cohort had bone disease only, and
29.8% had bone disease with LN involvement. Visceral disease
was present in 1,815 men (20.8%), and 565 men (6.4%) had LN-
only disease. Among patients with visceral disease, 791 (9.1%)
had lung metastases and 752 (8.6%) had liver metastases (173
patients had both liver and lung disease and were grouped in the
liver group). A small proportion of patients (3%) had adrenal,
brain, kidney, or other unspeciﬁed visceral metastases (in the
absence of liver metastases) and were excluded from the
hypothesis testing because of the small sample size. The fre-
quency of the site of metastases was comparable across studies,
perhaps reﬂecting similar inclusion criteria (Appendix Fig A1A,
online only). In addition, 19 patients with no metastases and 65
patients with missing site of metastases were excluded from the
analysis. The ﬁnal number of patients included in the meta-
analysis was 8,736.
Table 3 lists the baseline characteristics of patients by site of
metastases. There were some differences in baseline variables by the
site of metastases (Table 2). Not surprisingly, men who were in the
LN-only group had the lowest median PSA and median alkaline
phosphatase values and had higher median hemoglobin levels
compared with the other groups. By comparison, patients with
liver metastases had the highest median alkaline phosphatase and
Identification
No. of records identified 
through PubMed screening 
(n = 31)
No. of records identified 
through other sources
(n = 9)
ScreeningNo. of records screened
(n = 40)
No. of records
excluded
(n = 30)
No. of full-text articles 
assessed for eligibility
(n = 10)
Eligibility
No. excluded (n = 1)
sponsor became
financially insolvent 
No. of studies included 
in qualitative synthesis
(n = 9)
No. of studies included in
quantitative synthesis
(n = 9)
Included
Fig 1. PRISMA diagram.
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the lowest median hemoglobin levels. Men in the bone with nodal
disease group had the highest median PSA level.
Impact of Metastatic Site
The median OS duration by the site of metastases across the
trials is presented in Appendix Figure A1B. In general, median OS
in the metastatic site subgroups was roughly comparable across
trials, with the exception of MAINSAIL, which tested the addition
of lenalidomide to standard docetaxel therapy. Of studies that
allowed enrollment of LN-only patients, this study had both the
lowest number of LN-only men and also a discrepantly lowmedian
OS in this group of patients.
We sought to test the hypothesis that patients with lung
metastases would have a shorter median OS time than patients
with bonemetastasis. Figure 2A presents the Kaplan-Meier survival
curves by the site of metastases. The median OS time was 21.3 months
(95% CI, 20.8 to 21.9 months) in men with bone metastasis
compared with 19.4 months (95% CI, 17.8 to 20.7 months) in men
with lung metastases (Fig 2A).
The median OS times by trial and pooled across all trials are
presented in a forest plot (Fig 2B). Overall, there was marginal
variability in the observed median OS time for men with bone
metastases with or without nodal involvement and for men with
lung metastases across trials. The median OS times in men with
bone metastases with or without LN and in those with lung
metastases ranged from 17 to 23 months and 15 to 22 months,
respectively. The HRs for most of the trials were greater than 1,
indicating that men with lung metastases had shorter survival
duration than men with bone involvement, with the exception of
the VENICE and MAINSAIL trials. The pooled multivariable HR
of 1.14 (95% CI, 1.04 to 1.25) demonstrates that overall men with
lung metastases have a statistically signiﬁcant increased risk of
death compared with men with bone metastases (P = .007).
We also tested our second hypothesis that men with mCRPC
and liver metastases would have a shorter median OS time thanmen
with lung metastases. The median OS time was 19.4 months (95%
CI, 17.8 to 20.7 months) in men with lung metastases compared
with 13.5months (95%CI, 12.7 to 14.4months; Fig 2A) inmenwith
liver metastases. Minimal variability was observed in median OS
times by liver metastases across the nine trials, ranging from 9 to
14months (Fig 2C). The pooledmultivariable HR for menwith liver
metastases was 1.52 (95% CI, 1.35 to 1.73; P , .0001).
Table 2. Summary of Trials Included in the Meta-Analysis
Trial
Total Sample
Size (No. of patients)
Calendar Year
of Recruitment Study Population
Treatment Arms
(No. of patients)
SWOG 991610 674 October 1999 to
January 2003
Pathologically conﬁrmed
adenocarcinoma of the prostate and
progressive metastatic disease
(stage D1 or D2) despite androgen
ablative therapy and cessation of
antiandrogen treatment
Docetaxel + estramustine (338)
Mitoxantrone + prednisone (336)
TAX 32711 1,006 March 2000 to
June 2002
Men with metastatic hormone-
refractory prostate cancer
Docetaxel + prednisone (669)
Mitoxantrone + prednisone (337)
CALGB 9040113 1,050 May 2005 to
December 2007
Chemotherapy-naive progressive
metastatic castration-resistant
prostate cancer with ECOG
performance status # 2 and
adequate bone marrow, hepatic, and
renal function
Docetaxel + prednisone + bevacizumab (524)
Docetaxel + prednisone (526)
SWOG 042115 994 August 2006 to
May 2010
Pathologically conﬁrmed prostate
adenocarcinoma with bone
metastases on a bone scan,
unresponsive or refractory to
hormone treatment; Zubrod
performance status # 3
Atrasentan + docetaxel (498)
Placebo + docetaxel (496)
VENICE16 1,224 August 17, 2007,
to February 11,
2010
Histologically or cytologically conﬁrmed
prostate cancer and evidence of
metastatic disease that had
progressed on hormonal therapy or
after surgical castration
Docetaxel + prednisone + aﬂibercept (612)
Docetaxel + placebo (612)
ENTHUSE14 1,052 January 24, 2008,
to May 10, 2011
Men with histologically or cytologically
conﬁrmed prostate adenocarcinoma,
surgically castrated or continuously
medically castrated
Docetaxel + zibotentan (524)
Docetaxel +placebo (528)
READY17 1,522 October 30, 2008,
to April 11, 2011
Histologically conﬁrmed metastatic
prostate cancer that had progressed
despite castrate concentrations of
serum testosterone
Docetaxel + dasatinib (762)
Docetaxel + placebo (760)
MAINSAIL18 1,059 November 2009 to
November 2011
Conﬁrmed metastatic adenocarcinoma
of prostate that is refractory to
hormonal therapy
Docetaxel + prednisone + lenalidomide (533)
Docetaxel + prednisone + placebo (526)
SYNERGY19 1,022 August 2010
to April 2014
Histologically conﬁrmed metastatic
prostate cancer that had progressed
despite castrate concentrations of
serum testosterone
Docetaxel + prednisone + custirsen (510)
Docetaxel + prednisone (512)
Abbreviations: CALGB, Cancer and Leukemia Group B; ECOG, Eastern Cooperative Oncology Group; ENTHUSE, Endothelin A Use.
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Additional secondary analyses were conducted to estimate
the median OS in other categories for metastatic sites. Men with
LN-only disease had an observed median OS of 31.6 months
(95% CI, 27.9 to 35.5 months), and men with any visceral
disease had the lowest median OS time of 16.3 months (95% CI,
15.6 to 17.3 months; Appendix Fig A2, online only). In addition,
we estimated the pooled HR for death in men with LN-only
disease compared with men with bone with or without nodal
involvement. The HR was 0.61 (95% CI, 0.54 to 0.69; Appendix
Fig A3A, online only). Furthermore, the pooled HR for death
was 1.82 (95% CI, 1.67 to 2.0; Appendix Fig A3B) in men with
liver metastases compared with men with bone with or without
nodal involvement.
DISCUSSION
In this analysis of almost 9,000 patients, we conﬁrm that the
baseline presence of visceral disease is a negative prognostic factor
of OS in men with mCRPC who were subsequently treated with
docetaxel. This large sample size allowed us to estimate the
prevalence of disease site with reasonably high precision, and to test
for differences in outcomes among men with different metastatic
sites. Overall, almost 20.8% of men with mCRPC had visceral
disease, 8.6% of patients had liver metastases, and 9.1% of patients
had lung metastases (without liver involvement). The OS of men
treated with docetaxel who had liver metastases was substantially
worse than the OS of men with lung metastases. The median OS
time for 752 men with liver metastases was 13.5 months compared
with 19.4 months for 791 men with lung metastases (P , .0001).
With the exception of the VENICE trial, within this group of
patients with liver metastases, the OS seems to be homogenous,
with median OS ranging from 9 to 14 months. These results are
expected and conﬁrm prior published reports that patients with
liver metastases represent a poor-risk group.3-9 Although the
presence of liver metastases may simply reﬂect a lead time bias that
selects for patients with temporally more advanced disease, the
present data set does not allow testing of this hypothesis.22
In addition, we found differences in survival duration in men
with bone plus nodal disease compared with men with lung
metastases. Patients with lung metastases (with or without bone
disease) had shorter survival duration than patients with bone
disease with or without nodal involvement (P = .007). Not
surprisingly, men with LN-only disease had a longer survival
duration than men with bone involvement.
Our results suggest that prognostic subgroups should be
considered for novel therapies and in the design of future clinical
trials for menwithmCRPC. Furthermore, these results should help
guide clinical decision making for men with mCRPC. The data
included in this analysis are derived from well-designed and well-
conducted phase III trials involving the use of docetaxel for patients
with mCRPC10,11,13-19 closed to accrual between June 2002 (TAX
327)11 and November 2012 (SYNERGY).19 It is intriguing to note
that the variability in OS for each metastatic site subset across the
trials is not large, suggesting that the differences observed in
median OS from trial to trial could be explained by the relative
proportion of the metastatic subsets enrolled in each particular
trial.
The heterogeneity of men with mCRPC enrolled onto trials
and the substantially different outcomes among these subgroups
highlight the importance of reporting OS by disease location.
These data suggest that the distribution of patients across the
following categories should be routinely reported: LN-only
disease, bone with or without LN involvement with no vis-
ceral metastases, any lung metastases (but no liver), and any
liver metastases. Although the Prostate Cancer Clinical Trials
Working Group23 recommends the reporting of end points by
site of metastases, this has been only recently implemented in
several recent phase III trials.24-26
There are several limitations of this meta-analysis as a result of
its retrospective nature. First, data from more recent trials were
excluded, and the analysis could not include all known prognostic
factors across the trials. This highlights the difﬁculty in performing
this type of analysis as a result of the lack of harmonization in data
collected across phase III studies. In addition, neither imaging nor
imaging reports were centrally reviewed, and as such, we cannot
distinguish between nodular lung metastases and lymphangitic
spread, nor canwe assess the impact of themetastatic burden or the
number of metastases. Furthermore, most of the trials included in
this analysis were conducted before the approval and broad use of
abiraterone acetate or enzalutamide, which are now generally used
before the use of chemotherapy. Nevertheless, the sample size and
number of deaths in the pooled analysis were substantial, providing
excellent statistical power. Therefore, this analysis is likely to have
high validity. Finally, this analysis only applies to menwith mCRPC
who are treated with docetaxel, but because docetaxel is used
Table 3. Baseline Patients Characteristics by Site of Metastases
Characteristic
LN Only
(n = 565)
Bone With or Without LN
(n = 6,356) Lung (n = 791) Liver (n = 752) Total (n = 8,736)
Median age, years (25th-75th percentile) 69 (63-75) 68 (63-74) 69 (64-75) 69 (62-74) 68 (63-74)
White, % 77 74 77 74 74
PS* 0-1, % 96 95 94 91 94
Median PSA, ng/mL (25th-75th percentile) 58 (23-146) 89 (32-261) 77 (25-218) 93 (34-294) 86 (31-250)
Median alkaline phosphatase,
U/L (25th-75th percentile)
78 (64-101) 150 (91-308) 124 (81-242) 172 (92-342) 138 (86-287)
Median hemoglobin, g/dL (25th-75th percentile) 13.6 (12.4-14.9) 12.9 (11.7-14.0) 13 (11.8-14.3) 12.5 (11.3-13.7) 12.9 (11.7-14.1)
Abbreviation: LN, lymph node; PS, performance status; PSA, prostate-speciﬁc antigen.
*PS is Zubrod PS for Southwest Oncology Group 0421 trial, WHO PS for Endothelin A Use (ENTHUSE) study, Karnofsky PS for TAX 327, and Eastern Cooperative
Oncology Group PS for all other studies.
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Time Since Random Assignment (months)
OS
 (p
ro
ba
bi
lit
y)
LN        31.6 (27.9 to 35.5)
Bone  21.3 (20.8 to 21.9)
Lung  19.4 (17.8 to 20.7)
Liver  13.5 (12.7 to 14.4)
565 345 250 162 91 50 37
6,356 3,079 1,932 1,083 556 278 165
791 347 225 126 65 36 16
752
510
5,602
669
551
424
4,406
508
367 219 128 66 27 13 5
No. at risk
A
B
C
LN
Bone
Lung
Liver
0 6 12 18 24 30 36 42 48
0.2
0.4
0.6
0.8
1.0
Median OS (months, 95% CI)
0.0 1.0 2.0 3.0
P = .007
Hazard Ratio* (95% CI)
Lung Higher RiskBone (+/– LN) Higher Risk
Hazard Ratio
0.0 1.0 2.0 3.0
Hazard Ratio
P < .0001
Hazard Ratio* (95% CI)
Study Median OS (months, 95% CI)
Bone (+/– LN) Lung
Study Median OS (months, 95% CI)
Lung Liver
Liver Higher RiskLung Higher Risk
No. of patients (No. of deaths)
TAX 327
No. of patients (No. of deaths)
CALGB 90401
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
No. of patients (No. of deaths)
SWOG 0421
VENICE
ENTHUSE
READY
MAINSAIL
SYNERGY
SWOG 9916
TAX 327
CALGB 90401
SWOG 0421
VENICE
ENTHUSE
READY
MAINSAIL
SYNERGY
SWOG 9916
17.3 (15.9 to 20)
245 (160)
21.1 (18.9 to 26.1)
534 (280)
22.4 (21.4 to 23.8)
767 (721)
19.5 (17.6 to 20.9)
787 (605)
21.7 (20.3 to 23.4)
852 (619)
20.4 (19.1 to 22.2)
814 (416)
21.7 (20.9 to 23.2)
1,078 (641)
18.3 (17.4 to NR)
592 (116)
23.4 (21.7 to 25.5)
687 (397)
21.3 (20.8 to 21.9)
6,356 (3,955)
16.2 (11.2 to NR)
25 (16)
20.9 (13.0 to NR)
32 (17)
19 (16.3 to 21.8)
93 (90)
15.8 (14.2 to 18.3)
118 (100)
21.9 (17.8 to 26)
132 (86)
14.6 (9.3 to NR)
32 (21)
20.6 (18.8 to 25.4)
125 (79)
NR (13.6 to NR)
111 (21)
20.9 (17.4 to 24.5)
123 (87)
19.4 (17.8 to 20.7)
791 (517)
1.12 (0.67 to 1.88)
1.19 (0.73 to 1.94)
1.2 (0.96 to 1.49)
1.28 (1.04 to 1.59)
0.93 (0.74 to 1.16)
1.55 (1 to 2.4)
1 (0.79 to 1.26)
0.89 (0.55 to 1.44)
1.29 (1.02 to 1.64)
1.14 (1.04 to 1.25)
16.2 (11.2 to NR)
25 (16)
20.9 (13.0 to NR)
32 (17)
19 (16.3 to 21.8)
93 (90)
15.8 (14.2 to 18.3)
118 (100)
21.9 (17.8 to 26)
132 (86)
14.6 ( 9.3 to NR)
32 (21)
20.6 (18.8 to 25.4)
125 (79)
NR (13.6 to NR)
111 (21)
20.9 (17.4 to 24.5)
123 (87)
19.4 (17.8 to 20.7)
791 (517)
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Fig 2. (A) Kaplan-Meier overall survival (OS) curves by site ofmetastases. (B) Forest plot comparingmenwith lungmetastases tomenwith bonemetastaseswith or without
nodal involvement (reference group = bone with or without nodal involvement; Q = 8.42, df = 8, P = .393; I2 = 0.05). (*) Adjusted on age, performance status, and prostate-
speciﬁc antigen (with the exception of the summary hazard ratio). (C) Forest plotwith hazard ratios comparingmenwith livermetastases tomenwith lungmetastases (reference
group= lung;Q=7.93, df= 8,P= .441; I2 = 0.00). (*)Adjusted on age, performance status, andprostate-speciﬁc antigen (with the exceptionof thesummary hazard ratio). CALGB,
Cancer and Leukemia Group B; ENTHUSE, Endothelin A Use; LN, lymph node; NR, not reached.
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commonly in patients with mCRPC with visceral metastases, this
analysis also has practical utility.
In summary, menwith mCRPC treated with docetaxel who have
liver metastases had worse OS duration than men with lung meta-
stases. Men with lung metastases, in turn, had worse OS than men
with bone with or without LNmetastases. Thismeta-analysis provides
evidence-based rationale for the recommendations of the Prostate
Cancer Clinical TrialsWorking Group and for prospectively stratifying
for type of visceral metastases in future phase III trials.23,27 Our
understanding of what drives the development of different metastatic
patterns of this disease is limited and underscores the need to biopsy
patients with recurrences to identify underlying mechanisms and
develop novel treatment approaches for men with mCRPC.
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113 (98)
32.2 (25.8 to NR)
88 (46)
32.6 (25.9 to NR)
105 (47)
18.8 (18.8 to NR)
92 (13)
32.9 (27.6 to NR)
93 (42)
31.6 (27.9 to 35.5)
565 (278)
8.6 (5.3 to 21.5)
25 (20)
10.8 (5.9 to 17.0)
40 (31)
14.4 (13.3 to 19.7)
59 (58)
12.3 (9.8 to 15.4)
83 (66)
18.0 (16.2 to 20.6)
121 (97)
9.8 (7.4 to 14.1)
73 (59)
13.8 (11.9 to 16.9)
147 (104)
12.4 (10.3 to 16.1)
109 (40)
13.6 (11.3 to 19.6)
95 (71)
13.5 (12.7 to 14.4)
752 (546)
2.69 (1.67 to 4.31)
2.29 (1.57 to 3.34)
1.6 (1.22 to 2.1)
1.58 (1.22 to 2.04)
1.41 (1.13 to 1.75)
2.88 (2.16 to 3.84)
1.61 (1.3 to 1.98)
2.13 (1.48 to 3.07)
1.78 (1.37 to 2.31)
1.82 (1.67 to 2)
Fig A3. (A) Forest plot with hazard ratios comparing men with lymph node (LN)-only metastases to men with bone metastases with or without nodal involvement
(reference group = bone with or without nodal involvement; Q = 1.829, df = 6, P = .935, I2 = 0.00). (*) Adjusted on age, performance status, and prostate-speciﬁc antigen
(with the exception of the summary hazard ratio). The SWOG 0421 and Endothelin A Use (ENTHUSE) trials did not have patients with LN metastases and were excluded
from this comparison. (B) Forest plot with hazard ratios comparing men with liver metastases to men with bone metastases with or without nodal involvement (reference
group = bone with or without nodal involvement; Q = 8.064, df = 8, P = .427, I2 = 0.00). (*) Adjusted on age, performance status, and prostate-speciﬁc antigen (with the
exception of the summary hazard ratio). CALGB, Cancer and Leukemia Group B; NR, not reached; OS, overall survival.
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